Evaluation of Plasma Vitamin C Levels in a Population of Chronic Rheumatism in Immuno-Rheumatology

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Apr 19, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the levels of vitamin C in patients with chronic inflammatory rheumatism, specifically those with lupus or spondyloarthritis. Researchers want to understand how vitamin C, which is important for many body functions, might help with pain and fatigue that some patients experience, even when their disease is under control. Vitamin C is known for its role in making collagen and may also have properties that help reduce pain by influencing certain chemicals in the body.

To participate in this trial, individuals must be over 18 years old and diagnosed with chronic inflammatory rheumatism that is currently in remission or showing low activity. Participants should have ongoing pain that isn’t fully explained by their rheumatic condition. Pregnant or nursing women and those involved in other clinical trials recently are not eligible. For those who qualify, they will provide consent and will be monitored to see how vitamin C levels may relate to their pain and overall health. This could potentially lead to new ways to manage symptoms for patients with these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patient over 18 years-old,
• • followed for chronic inflammatory rheumatism (RIC): spondylo-arthritis (including spondylitis and psoriatic rheumatism) and lupus,
• • with RIC in remission or low activity definec according to the following criteria: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) criteria and Bath Ankylosing Spondylitis Fonctional Index (BASFI) questionnaire for spondylitis and psoriatic rheumatism, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2K score for lupus,
• • having given written consent after written and oral information,
• • member of the social security system,
• • basic treatment for the disease not modified for at least 6 months, without modification at baseline
• • persistence of painful complaints not objectively explained by his RIC.
• Exclusion Criteria:
• • pregnant or nursing patient,
• • patient protected by law or under guardianship or curatorship, or not able to participate in a clinical trial under L.1121-16 article of French Public Health Regulations,
• • patient participating in or having participated in another drug clinical trial in the month prior to inclusion.